Cargando…

Women and Diabetes: Preventing Heart Disease in a New Era of Therapies

Despite major advances in cardiovascular research over the past decade, women with type 2 diabetes have a high risk of cardiovascular events. Several factors contribute to the poor prognosis for women, including higher levels of frailty and comorbidities, but their cardiovascular risk is underestima...

Descripción completa

Detalles Bibliográficos
Autores principales: Galati, Giuseppe, Sabouret, Pierre, Germanova, Olga, Bhatt, Deepak L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576483/
https://www.ncbi.nlm.nih.gov/pubmed/34777580
http://dx.doi.org/10.15420/ecr.2021.22
_version_ 1784595885746814976
author Galati, Giuseppe
Sabouret, Pierre
Germanova, Olga
Bhatt, Deepak L
author_facet Galati, Giuseppe
Sabouret, Pierre
Germanova, Olga
Bhatt, Deepak L
author_sort Galati, Giuseppe
collection PubMed
description Despite major advances in cardiovascular research over the past decade, women with type 2 diabetes have a high risk of cardiovascular events. Several factors contribute to the poor prognosis for women, including higher levels of frailty and comorbidities, but their cardiovascular risk is underestimated and there is suboptimal implementation and uptitration of new evidence-based therapies, leading to high morbidity and mortality. Recent studies highlight the need for better management of diabetes in women that can be pursued and achieved in light of recent results from randomised controlled trials demonstrating evidence of the benefits of new therapeutic strategies in improving cardiovascular outcomes and quality of life of women covering the entire cardiovascular continuum. This review critically discusses the multiple benefits for women of new pharmacological treatments, such as glucagon-like peptide-1 receptor agonists, sodium–glucose cotransporter type 2 inhibitors (SGLT2i), proprotein convertase subtilisin/kexin type 9 inhibitors, inclisiran, icosapent ethyl and bempedoic acid in preventing cardiovascular events, and treatments, such as angiotensin receptor neprilysin inhibitors, SGLT2i, vericiguat and omecamtiv mecarbil, for preventing heart failure.
format Online
Article
Text
id pubmed-8576483
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Radcliffe Cardiology
record_format MEDLINE/PubMed
spelling pubmed-85764832021-11-12 Women and Diabetes: Preventing Heart Disease in a New Era of Therapies Galati, Giuseppe Sabouret, Pierre Germanova, Olga Bhatt, Deepak L Eur Cardiol Women and Heart Disease Despite major advances in cardiovascular research over the past decade, women with type 2 diabetes have a high risk of cardiovascular events. Several factors contribute to the poor prognosis for women, including higher levels of frailty and comorbidities, but their cardiovascular risk is underestimated and there is suboptimal implementation and uptitration of new evidence-based therapies, leading to high morbidity and mortality. Recent studies highlight the need for better management of diabetes in women that can be pursued and achieved in light of recent results from randomised controlled trials demonstrating evidence of the benefits of new therapeutic strategies in improving cardiovascular outcomes and quality of life of women covering the entire cardiovascular continuum. This review critically discusses the multiple benefits for women of new pharmacological treatments, such as glucagon-like peptide-1 receptor agonists, sodium–glucose cotransporter type 2 inhibitors (SGLT2i), proprotein convertase subtilisin/kexin type 9 inhibitors, inclisiran, icosapent ethyl and bempedoic acid in preventing cardiovascular events, and treatments, such as angiotensin receptor neprilysin inhibitors, SGLT2i, vericiguat and omecamtiv mecarbil, for preventing heart failure. Radcliffe Cardiology 2021-10-21 /pmc/articles/PMC8576483/ /pubmed/34777580 http://dx.doi.org/10.15420/ecr.2021.22 Text en Copyright © 2021, Radcliffe Cardiology https://creativecommons.org/licenses/by-nc/4.0/This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.
spellingShingle Women and Heart Disease
Galati, Giuseppe
Sabouret, Pierre
Germanova, Olga
Bhatt, Deepak L
Women and Diabetes: Preventing Heart Disease in a New Era of Therapies
title Women and Diabetes: Preventing Heart Disease in a New Era of Therapies
title_full Women and Diabetes: Preventing Heart Disease in a New Era of Therapies
title_fullStr Women and Diabetes: Preventing Heart Disease in a New Era of Therapies
title_full_unstemmed Women and Diabetes: Preventing Heart Disease in a New Era of Therapies
title_short Women and Diabetes: Preventing Heart Disease in a New Era of Therapies
title_sort women and diabetes: preventing heart disease in a new era of therapies
topic Women and Heart Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576483/
https://www.ncbi.nlm.nih.gov/pubmed/34777580
http://dx.doi.org/10.15420/ecr.2021.22
work_keys_str_mv AT galatigiuseppe womenanddiabetespreventingheartdiseaseinaneweraoftherapies
AT sabouretpierre womenanddiabetespreventingheartdiseaseinaneweraoftherapies
AT germanovaolga womenanddiabetespreventingheartdiseaseinaneweraoftherapies
AT bhattdeepakl womenanddiabetespreventingheartdiseaseinaneweraoftherapies